HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Galiè, N. Search for Related Content PubMed PubMed Citation Articles by Galiè, N.

CLINICAL STUDY: PULMONARY HYPERTENSION

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

Nazzareno Galiè, MD^*,*, Marc Humbert, MD, Jean-Luc Vachiéry, MD, CarmineDario Vizza, MD, Meinhard Kneussl, MD^||, Alessandra Manes, MD^*, Olivier Sitbon, MD, Adam Torbicki, MD^¶, Marion Delcroix, MD^#, Robert Naeije, MD, Marius Hoeper, MD^**, Ari Chaouat, MD, Sophie Morand, MD, Bruno Besse, MD, Gerald Simonneau, MD the Arterial Pulmonary Hypertension and Beraprost European Trial (ALPHABET) Study Group

^* Institute of Cardiology, University of Bologna, Bologna, Italy
Division of Pulmonary and Critical Care Medicine, Antoine Béclère Hospital, Clamart, Paris-Sud University, Clamart, France
Departement de Cardiologie et Laboratoire de Physiologie, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
Department of Cardiology, University of Roma "La Sapienza," Rome, Italy
^|| Allgemeines Krankenhaus der Stadt Wien, University of Vienna, Vienna, Austria
^¶ Department of Chest Medicine, National Institute of Tuberculosis and Lung Disease, Warsaw, Poland
^# Department of Pneumology, Gasthuisberg University Hospital, Leuven, Belgium
^** Abteilung Pneumologie, Medizinische Hochschule Hannover, Hannover, Germany
Service de Pneumologie, Centre Hospitalier Hautepierre, Strasbourg, France
Laboratoire Aventis, Paris, France

Manuscript received November 6, 2001; revised manuscript received January 28, 2002, accepted February 6, 2002.

^* Reprint requests and correspondence: Dr. Nazzareno Galiè, Istituto di Cardiologia, Università di Bologna, via Massarenti, 9, 40138-Bologna, Italy.
n.galie{at}bo.nettuno.it

	Abstract

Top Abstract Methods Results Discussion References

 
OBJECTIVES: The purpose of this study was to assess the efficacy and safety of beraprost sodium, an orally active prostacyclin analogue, in New York Heart Association (NYHA) functional class II and III patients with pulmonary arterial hypertension (PAH).

BACKGROUND: Pulmonary arterial hypertension is a life-threatening disease for which continuous intravenous infusion of prostacyclin has been proven effective. However, this treatment is associated with serious complications arising from the complex delivery system.

METHODS: In this double-blind, placebo-controlled study, 130 patients with PAH were randomized to the maximal tolerated dose of beraprost (median dose 80 µg four times a day) or to placebo for 12 weeks. The primary end point was the change in exercise capacity assessed by the 6-min walk test. Secondary end points included changes in Borg dyspnea index, cardiopulmonary hemodynamics and NYHA functional class.

RESULTS: Patients treated with beraprost improved exercise capacity and symptoms. The difference between treatment groups in the mean change of 6-min walking distance at week 12 was 25.1 m (95% confidence interval [CI]: 1.8 to 48.3, p = 0.036). The difference in the mean change of Borg dyspnea index was –0.94 (95% CI: –1.63 to –0.24, p = 0.009). In the sub-group of patients with primary pulmonary hypertension, the difference in the mean change of 6-min walking distance was 46.1 m (95% CI: 3.0 to 89.3, p = 0.035). Cardiopulmonary hemodynamics and NYHA functional class had no statistically significant changes. Drug-related adverse events were common in the titration phase and decreased in the maintenance period.

CONCLUSIONS: Beraprost improves exercise capacity and symptoms in NYHA functional class II and III patients with PAH and, in particular, in those with primary pulmonary hypertension.

Abbreviations and Acronyms   CI   confidence interval   HIV   human immunodeficiency virus   PAH   pulmonary arterial hypertension   NYHA   New York Heart Association

Beraprost sodium is the first chemically stable and orally active prostacyclin analogue (22). In experimental studies, beraprost sodium has been shown to exert a protective effect on the development of monocrotaline-induced pulmonary hypertension (23). Uncontrolled and retrospective experiences in patients with primary pulmonary hypertension have preliminarily shown that long-term oral treatment with beraprost sodium improves hemodynamics (24) and prognosis (25).

We report on the results of a randomized, double-blind, placebo-controlled, multicenter study designed to determine the effects of 12-week oral administration of beraprost sodium on exercise capacity, symptoms and cardiopulmonary hemodynamics in NYHA class II and III patients with PAH.

	Methods

Top Abstract Methods Results Discussion References

 
Patients selection.   Patients eligible for this study were males or females over 8 years of age with PAH (1) in NYHA functional classes II and III, including primary pulmonary hypertension, pulmonary hypertension associated with collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension and HIV infection. A baseline 6-min walking distance between 50 and 500 m, a mean pulmonary artery pressure >25 mm Hg and a pulmonary capillary wedge pressure <15 mm Hg were required for inclusion. Patients were excluded if they had received long-term treatment with other prostacyclin analogues within one month of enrolment. The study was conducted in accordance with good clinical practices, the current version of the declaration of Helsinki and with local regulations. The local ethics review committee approved the protocol, and written informed consent was obtained from all patients.

Study design
This study was designed as a prospective, double-blind, randomized, placebo-controlled, 12-week trial conducted in 13 centers in Europe. The first six weeks of the study were considered as a titration period in which the dose of beraprost sodium was increased weekly until the maximal tolerated dose was achieved. Patients received one tablet (20 µg) of beraprost sodium or matching placebo four times a day for the first week, and the dose was increased by 20 µg or matching placebo four times a day each week. In case of intolerable side effects, the dose was reduced to that of the previous week, and this was considered as the maximal tolerated dose. Therefore, the up-titration was based on side effects and not on clinical efficacy, in order to administer the highest tolerated dose. The maximal dose allowed in the study was 120 µg four times a day at week 6. The maximal tolerated dose was kept constant during the maintenance period between week 7 and week 12. Side effects limiting dose increase were moderate to severe flushing, headache and diarrhea and usually occurred 1 to 2 h after single-dose intake. All patients were enrolled in an open-label study with beraprost sodium after the completion of the randomized study.

Outcome measures
Patients were evaluated at baseline, week 6 and week 12. The primary efficacy parameter was exercise capacity measured by the distance a patient could walk in 6 min (6-min walk test) at week 12. The 6-min walk test was performed after standardized procedures (26) 2 to 4 h after drug intake.

Secondary measures of efficacy included the Borg dyspnea index (27) assessed immediately after completion of the 6-min walk test and cardiopulmonary hemodynamics measured by right heart catheterization at baseline and week 12. Cardiac index (l/min/m²) was computed as cardiac output divided by body surface area; pulmonary vascular resistance index (U/m²) was calculated using standard formula: mean pulmonary artery pressure–pulmonary capillary wedge pressure/cardiac index. Secondary measures of efficacy also included the NYHA functional class and the reduction in all-cause mortality or hospitalization for worsening of symptoms related to pulmonary hypertension. Safety was assessed by adverse event recording and laboratory assessment.

Statistical analysis
The sample size was estimated under the assumptions of a two-sided alpha probability of 0.05, an 80%-power, an expected treatment difference for the change from baseline in 6-min walk test of 40 m and an SD of 70 m. Under these conditions, the study’s 1:1 randomization required a sample size of at least 50 evaluable patients in each group. Assuming a 10% drop-out rate, planned recruitment was for a total of 110 patients (55 per group).

Analysis were performed in the intent-to-treat population that included all patients who were randomized, received at least one dose of study treatment and who also had a valid assessment of the primary end point (change from baseline in exercise capacity after 12 weeks of treatment) after applying the imputation rules for missing data.

In the event that no data were available at week 12 for the primary or secondary efficacy variable, the week 6 values or, if lacking, the baseline values were carried forward and used as values at week 12 (last observation carried forward). Two additional methods for missing data imputation were prospectively planned for the primary efficacy variable to ensure robustness of the results: the "left censored data" and "worst quartile" methods.

The significance levels of the difference between treatment groups for the 6-min walk test were evaluated with analysis of covariance (ANCOVA) (i.e., analysis of variance adjusted by baseline values, using the change from baseline to week 12 for each patient [SAS, version 8, Cary, North Carolina]). This test was performed at 5% two-tail level. The changes from baseline to week 12 of Borg dyspnea index and hemodynamic parameters were compared between treatment groups with ANCOVA. Changes from baseline to week 12 in NYHA classification (ordinal scale) were analyzed using Mantel-Haenszel method. Values with a ± symbol are the mean ± SD. All the reported p values were two-tailed.

	Results

Top Abstract Methods Results Discussion References

 
One hundred thirty patients were included in the study (65 beraprost/65 placebo). At the end of 12 weeks, mean dose of drug was 80 ± 35 µg four times a day (median = 80 µg four times a day) in the beraprost sodium group, and the hypothetical dose in the placebo group was 111 ± 22 µg four times a day.

Baseline characteristics.   Baseline demographic, clinical and hemodynamic characteristics of the two groups are shown in Table 1. The groups did not differ significantly in etiology of PAH, in NYHA functional class, in distance walked at the 6-min walk test or in severity of pulmonary hemodynamics. In the beraprost sodium group, there was a nonsignificant trend toward a higher prevalence of patients with primary pulmonary hypertension as well as a trend toward a lower mean distance walked at baseline.

View larger version (16K): [in this window] [in a new window]   Figure 1 Change in 6-min walking distance from baseline to week 6 and week 12 in the placebo and beraprost groups. Values are expressed as mean ± standard error. p = 0.036 for no difference between treatment groups with analysis of covariance at week 12.

View larger version (14K): [in this window] [in a new window]   Figure 2 Mean change from baseline in results of the 6-min walk test at week 12 in all patients (ALL), in patients with primary pulmonary hypertension (PPH) and in patients with associated forms of pulmonary hypertension (APH). Analysis of covariance adjusted by baseline values showed that the mean distance walked in 6 min increased in patients who received beraprost (solid bars) compared with patients who received placebo (open bars) in ALL (p = 0.036) and in PPH patients (p = 0.035). No statistically significant changes were observed in APH patients (p = 0.676). Numbers at the tops of the bars = exact mean rates; lines = standard error of the mean. N = the number of patients in each group.

View larger version (13K): [in this window] [in a new window]   Figure 3 Mean change in Borg dyspnea index from baseline to week 12 in all patients (ALL), in patients with primary pulmonary hypertension (PPH) and in patients with associated forms of pulmonary hypertension (APH). Analysis of covariance adjusted by baseline values showed that Borg dyspnea index improved (decreased) in patients who received beraprost (solid bars) and worsened (increased) in the placebo group (open bars) over 12 weeks in ALL (p = 0.009) and in PPH patients (p = 0.013). No statistically significant changes were observed in APH patients (p = 0.935). Numbers at the tops of the bars = exact mean rates; lines = standard error of the mean. N = the number of patients in each group.

During the 12-week study period, four patients (6%) in the beraprost sodium group and three (5%) patients in the placebo group either died or were hospitalized for worsening of symptoms related to pulmonary hypertension. Two patients died, one in the beraprost sodium group due to progressive right heart failure and one in the placebo group due to septic shock.

Cardiopulmonary hemodynamics
The changes in hemodynamic measures from baseline to week 12 are shown in Table 2. The beraprost and placebo treated patients had small variations of hemodynamic parameters, and no statistically significant changes were detected.

	Discussion

Top Abstract Methods Results Discussion References

 
Exercise capacity.   This double-blind, placebo-controlled, 12-week study demonstrated that the oral prostacyclin analogue beraprost sodium improves exercise capacity and symptoms in patients with PAH. As in other trials performed in this patient population, the primary end point of this study was the 6-min walking distance that has been shown to be an independent predictor of mortality (16,28). In our study the robustness of the 6-min walk test results were confirmed by different statistical analysis. So far, therapeutic trials in PAH have included more severely compromised subjects in NYHA functional class III or IV (16,18). For the first time, our study has included a larger proportion (49% of overall population) of less severe patients in NYHA functional class II (Table 1). Interestingly, no significant interaction was observed between NYHA functional class and treatment effect, suggesting that the favorable effects of beraprost sodium were similar in both NYHA functional class II and III patients.

Sub-group analysis
Sub-group analysis has shown that the improvement in the 6-min walk test was achieved only in patients with primary pulmonary hypertension, while no statistically significant changes were observed in the associated forms group (Fig. 2). The treatment effect observed in NYHA class II and III patients with primary pulmonary hypertension was 45 m. In a previous study with intravenous epoprostenol, carried out in a more severe patient population (NYHA functional class III and IV), the treatment effect was 47 m (16).

The absence of significant improvement of exercise capacity in associated forms of pulmonary hypertension could be attributed to different causes. Firstly, in this trial the group of associated forms was heterogeneous including 36% of patients with congenital systemic-to-pulmonary shunts, 32% with portal hypertension, 19% with collagen vascular disease and 13% with HIV infection. Analysis of the effects on each individual sub-group is prevented by the small sample size. So far, a single controlled clinical study has demonstrated a positive effect of epoprostenol on exercise capacity in patients with pulmonary hypertension associated with scleroderma (18). Treatment with prostanoids of all the other forms of associated pulmonary hypertension have been evaluated in uncontrolled studies (17), and the favorable effects require further confirmations. Secondly, the doses of beraprost sodium were substantially lower in patients with associated forms of pulmonary hypertension than in patients with primary pulmonary hypertension (62 ± 36 µg four times a day vs. 96 ± 35 µg four times a day, respectively). Dose increase was usually limited by symptoms like headache, flushing and diarrhea, and it is possible that patients with associated conditions are more predisposed to these side effects. In fact, patients with portal hypertension, HIV infection and collagen vascular disease have a multi-organ involvement that could interfere with beraprost sodium tolerability. It is unclear from our data if the higher dose of beraprost sodium tolerated by patients with primary pulmonary hypertension may explain the better results obtained on 6-min walking distance. Finally, a 12-week study may be too short to demonstrate a beneficial effect of prostanoid therapy in the associated forms group. In fact, patients with pulmonary hypertension associated with systemic-to-pulmonary shunt or to portal hypertension (67% of associated forms in this trial) may show a slower rate of clinical deterioration (29) and a longer preservation of the cardiac output. This evidence is supported in our study by the absence of a reduction of the 6-min walking distance in placebo-treated patients with the associated forms, whereas the placebo-treated patients with primary pulmonary hypertension showed a significant decrease of exercise capacity (Fig. 2).

Symptoms and outcome
In the overall population, the improvement in the 6-min walking distance was associated with a concomitant significant improvement in the perception of dyspnea, as assessed by the reduction of Borg dyspnea score (Fig. 3). On the other hand, we observed no statistically significant improvement of NYHA functional class in patients treated with beraprost, as compared with placebo. In addition, the rate of the combined end point of death or hospitalization was low and similar in both beraprost sodium and placebo groups (6% vs. 5%, respectively). Possible explanations for these findings include the high proportion of NYHA functional class II patients at baseline and the short duration of the study that was not specifically designed to detect a difference in these secondary end points.

Cardiopulmonary hemodynamics
Unlike the previous studies with epoprostenol (18), we did not find statistically significant improvements in resting hemodynamic variables even if small favorable trends in the beraprost sodium group were observed. Possible reasons for explaining these differences include the greater severity of baseline hemodynamic changes in earlier epoprostenol trials and the small deterioration we observed in the placebo group.

Safety and tolerability
Despite the high doses of beraprost sodium used in this study, the safety profile of the drug was excellent with neither systemic hypotension nor hepatic, renal or hematologic side effects. Adverse events commonly observed with all prostacyclin analogues (headache, flushing, jaw pain, diarrhea and nausea) were frequent during the titration period when the highest possible doses were tested, while the tolerability of the drug was much better in the maintenance phase.

Conclusions
Oral beraprost sodium therapy is effective in improving functional capacity and symptoms in NYHA functional class II and III patients with PAH and, in particular, in those with primary pulmonary hypertension. The benefit/risk ratio of beraprost sodium appears to be satisfactory. However, further studies are needed to define the long-term effect of this treatment on morbidity and mortality of patients with PAH.

Additional members of the Alphabet study group
Giulio Boggian, MD, Elena Mazzoni, MD, Federica Pelino, MD, University of Bologna, Italy; Roberto Badagliacca, MD, University of Roma "La Sapienza," Italy; Pawel Kuca, MD, Marcin Kurzyna, MD, National Institute of Lung Disease, Warsaw, Poland; Edda Spiekerkoetter, MD, Medizinische Hochschule Hannover, Germany; Christophe Pison, MD, Centre Hospitalier Universitaire, Grenoble, France; Francois Chabot, MD, CHU de Nancy, France; Benoit Wallaert, MD, Hôpital Calmette, Lille, France; Irene Lang, MD, University of Wien, Austria; Christian Opitz, MD, Universität zu Berlin, Germany.

	Footnotes

 
Supported by a grant from Laboratoire Aventis, Paris, France.

	References

Top Abstract Methods Results Discussion References

 

1. Nomenclature Committee. Nomenclature and classification of pulmonary hypertension. Rich S. http://www.who.int/ncd/cvd/pph.htmlPrimary Pulmonary Hypertension: Executive Summary From the World Symposium—Primary Pulmonary Hypertension 1998. Geneva: World Health Organization; 1998. p. 25–27
2. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336:111–117[Free Full Text]
3. Galiè N, Manes A, Uguccioni L, et al. Primary pulmonary hypertension: insights into pathogenesis from epidemiology. Chest. 1998;114 3(Suppl):184S–194S
4. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343–349[Medline]
5. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology. 2001;40:453–459[Abstract/Free Full Text]
6. Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults (second of two parts). N Engl J Med. 2000;342:334–342[Free Full Text]
7. Hervé P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J. 1998;11:1153–1166[Abstract]
8. Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation. 1994;89:2722–2727[Abstract/Free Full Text]
9. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension registry. Circulation. 1989;80:1198–1206[Abstract/Free Full Text]
10. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663–665[CrossRef][Medline]
11. Gryglewski RJ. Interactions between endothelial mediators. Pharmacol Toxicol. 1995;77:1–9[Medline]
12. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol. 1995;48:890–896[Abstract]
13. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70–75[Abstract]
14. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925–1932[Abstract/Free Full Text]
15. Badesch DB, Orton EC, Zapp LM, et al. Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. Am J Respir Cell Mol Biol. 1989;1:489–498
16. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension study group. N Engl J Med. 1996;334:296–302[Abstract/Free Full Text]
17. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99:1858–1865[Abstract/Free Full Text]
18. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med. 2000;132:425–434[Abstract/Free Full Text]
19. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med. 1999;130:740–743[Abstract/Free Full Text]
20. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2000;162:1846–1850[Abstract/Free Full Text]
21. Galiè N. Do we need controlled clinical trials in pulmonary arterial hypertension? Eur Respir J. 2001;17:1–3[Free Full Text]
22. Nishio S, Kurumatani H. Pharmacological and clinical properties of beraprost sodium, orally active prostacyclin analogue. Nippon Yakurigaku Zasshi. 2001;117:123–130[Medline]
23. Miyata M, Ueno Y, Sekine H, et al. Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension. J Cardiovasc Pharmacol. 1996;27:20–26[CrossRef][Medline]
24. Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet. 1997;349:1365[CrossRef][Medline]
25. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999;34:1188–1192[Abstract/Free Full Text]
26. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic failure. Can Med Assoc J. 1985;132:919–923[Abstract]
27. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377–381[Medline]
28. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161:487–492[Abstract/Free Full Text]
29. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant. 1996;15:100–105[Medline]

This article has been cited by other articles:

				J. Le Pavec, R. Souza, P. Herve, D. Lebrec, L. Savale, C. Tcherakian, X. Jais, A. Yaici, M. Humbert, G. Simonneau, et al. Portopulmonary Hypertension: Survival and Prognostic Factors Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 637 - 643. [Abstract] [Full Text] [PDF]

				K. Boutet, D. Montani, X. Jais, A. Yaici, O. Sitbon, G. Simonneau, and M. Humbert Review: Therapeutic advances in pulmonary arterial hypertension Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 249 - 265. [Abstract] [PDF]

				N. Galie, H. Olschewski, R. J. Oudiz, F. Torres, A. Frost, H. A. Ghofrani, D. B. Badesch, M. D. McGoon, V. V. McLaughlin, E. B. Roecker, et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 Circulation, June 10, 2008; 117(23): 3010 - 3019. [Abstract] [Full Text] [PDF]

				M. Gomberg-Maitland and H. Olschewski Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur. Respir. J., April 1, 2008; 31(4): 891 - 901. [Abstract] [Full Text] [PDF]

				T. Ohno, J. Muneuchi, K. Ihara, T. Yuge, Y. Kanaya, S. Yamaki, and T. Hara Pulmonary Hypertension in Patients With Congenital Portosystemic Venous Shunt: A Previously Unrecognized Association Pediatrics, April 1, 2008; 121(4): e892 - e899. [Abstract] [Full Text] [PDF]

				National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Heart, March 1, 2008; 94(Suppl_1): i1 - i41. [Full Text] [PDF]

				National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41. [Full Text] [PDF]

				D. L. Helman Jr, A. W. Brown, J. L. Jackson, and A. F. Shorr Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension: Potential Implications for the Design of Future Clinical Trials Chest, September 1, 2007; 132(3): 764 - 772. [Abstract] [Full Text] [PDF]

				M. M. Hoeper Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value Eur. Respir. J., March 1, 2007; 29(3): 432 - 434. [Full Text] [PDF]

				G.-P. Diller and M. A. Gatzoulis Pulmonary Vascular Disease in Adults With Congenital Heart Disease Circulation, February 27, 2007; 115(8): 1039 - 1050. [Abstract] [Full Text] [PDF]

				M. M. Hoeper, S. H. Lee, R. Voswinckel, M. Palazzini, X. Jais, A. Marinelli, R. J. Barst, H. A. Ghofrani, Z.-C. Jing, C. Opitz, et al. Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2546 - 2552. [Abstract] [Full Text] [PDF]

				O. Distler, F. Behrens, D. Huscher, I. Foeldvari, A. Zink, P. Nash, C. P. Denton, M. Humbert, M. Matucci-Cerinic, J. Seibold, et al. Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis Rheumatology, December 1, 2006; 45(12): 1455 - 1457. [Full Text] [PDF]

				H. A. Ghofrani, R. Voswinckel, F. Reichenberger, N. Weissmann, R. T. Schermuly, W. Seeger, and F. Grimminger Hypoxia- and non-hypoxia-related pulmonary hypertension - Established and new therapies Cardiovasc Res, October 1, 2006; 72(1): 30 - 40. [Abstract] [Full Text] [PDF]

				O. Distler and A. Pignone Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment Rheumatology, October 1, 2006; 45(suppl_4): iv22 - iv25. [Abstract] [Full Text] [PDF]

				G. Riemekasten and C. Sunderkotter Vasoactive therapies in systemic sclerosis Rheumatology, October 1, 2006; 45(suppl_3): iii49 - iii51. [Abstract] [Full Text] [PDF]

				V. V. McLaughlin and M. D. McGoon Pulmonary Arterial Hypertension Circulation, September 26, 2006; 114(13): 1417 - 1431. [Full Text] [PDF]

				T. Adriaenssens, M. Delcroix, K. Van Deyk, and W. Budts Advanced therapy may delay the need for transplantation in patients with the Eisenmenger syndrome Eur. Heart J., June 2, 2006; 27(12): 1472 - 1477. [Abstract] [Full Text] [PDF]

				K. Niwano, M. Arai, N. Koitabashi, S. Hara, A. Watanabe, K. Sekiguchi, T. Tanaka, T. Iso, and M. Kurabayashi Competitive Binding of CREB and ATF2 to cAMP/ATF Responsive Element Regulates eNOS Gene Expression in Endothelial Cells Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 1036 - 1042. [Abstract] [Full Text] [PDF]

				M. M. Hoeper, I. Markevych, E. Spiekerkoetter, T. Welte, and J. Niedermeyer Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Eur. Respir. J., November 1, 2005; 26(5): 858 - 863. [Abstract] [Full Text] [PDF]

				H. H. Leuchte, M. Holzapfel, R. A. Baumgartner, C. Neurohr, M. Vogeser, and J. Behr Characterization of Brain Natriuretic Peptide in Long-term Follow-up of Pulmonary Arterial Hypertension Chest, October 1, 2005; 128(4): 2368 - 2374. [Abstract] [Full Text] [PDF]

				H. F. Nadrous, P. A. Pellikka, M. J. Krowka, K. L. Swanson, N. Chaowalit, P. A. Decker, and J. H. Ryu Pulmonary Hypertension in Patients With Idiopathic Pulmonary Fibrosis Chest, October 1, 2005; 128(4): 2393 - 2399. [Abstract] [Full Text] [PDF]

				C. F. Opitz, R. Wensel, J. Winkler, M. Halank, L. Bruch, F.-X. Kleber, G. Hoffken, S. D. Anker, A. Negassa, S. B. Felix, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension Eur. Heart J., September 2, 2005; 26(18): 1895 - 1902. [Abstract] [Full Text] [PDF]

				L. J. Rubin and D. B. Badesch Evaluation and Management of the Patient with Pulmonary Arterial Hypertension Ann Intern Med, August 16, 2005; 143(4): 282 - 292. [Abstract] [Full Text] [PDF]

				H.-J. Seyfarth, H. Pankau, S. Hammerschmidt, J. Schauer, H. Wirtz, and J. Winkler Bosentan Improves Exercise Tolerance and Tei Index in Patients With Pulmonary Hypertension and Prostanoid Therapy Chest, August 1, 2005; 128(2): 709 - 713. [Abstract] [Full Text] [PDF]

				S. L. Merklinger, P. L. Jones, E. C. Martinez, and M. Rabinovitch Epidermal Growth Factor Receptor Blockade Mediates Smooth Muscle Cell Apoptosis and Improves Survival in Rats With Pulmonary Hypertension Circulation, July 19, 2005; 112(3): 423 - 431. [Abstract] [Full Text] [PDF]

				K. Ford Pulmonary artery hypertension: new drug treatment in children Arch. Dis. Child. Ed. Pract., June 1, 2005; 90(1): ep15 - ep20. [Full Text] [PDF]

				E. Bossone, B. D. Bodini, A. Mazza, and L. Allegra Pulmonary Arterial Hypertension: The Key Role of Echocardiography Chest, May 1, 2005; 127(5): 1836 - 1843. [Abstract] [Full Text] [PDF]

				A. J Lee, T. B Chiao, and M. P Tsang Sildenafil for Pulmonary Hypertension Ann. Pharmacother., May 1, 2005; 39(5): 869 - 884. [Abstract] [Full Text] [PDF]

				Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278. [Full Text] [PDF]